Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

Verastem (VSTM) announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in ...

Verastem Oncology has unveiled updated early-stage data from its RAMP 205 trial in metastatic pancreatic cancer, bolstering ...

BOSTON - Verastem Oncology (NASDAQ: VSTM), a clinical-stage biopharmaceutical company with a market capitalization of $418 million, has announced positive results from the RAMP 205 Phase 1/2 trial ...

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic ...

The most notable development for Verastem has been the U.S. Food and Drug Administration (FDA) approval of its drug Avmapki Fakzynja Co-Pack (Av-Fak) for the treatment of low-grade serous ovarian ...

Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian ...

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence applications for precision medicine with a market capitalization of $11 billion and impressive year-to-date returns of 89%, ...

Verastem is also evaluating avutometinib in combination with defactinib and other agents as a potential treatment for patients with advanced pancreatic cancer (RAMP 205; NCT05669482) and advanced ...

Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, today announced new data to be presented at the 2025 American Society of ...